Transient liver enzyme derangement following Remdesivir use: a case series
Remdesivir, a nucleotide analog RNA polymerase inhibitor, which was originally evaluated in clinical trials to thwart the Ebola outbreak in 2014, has shown in vitro efficacy against SARS-CoV-2. Experience on its efficacy and safety in COVID-19 is accumulating. In COVID-19, Remdesivir therapy is given intravenously for 5 to 10 days and is frequently accompanied by transient, reversible mild-to-moderate elevations in serum aminotransferase levels but has been only rarely linked to instances of clinically apparent liver injury as a drug-induced liver injury (DILI). It may be caused by direct toxicity possibly due to inhibition of mitochondrial RNA polymerase. Here, we have discussed two cases where liver enzyme levels increased dramatically on the day next after initiating Remdesivir. Case one and two showed grade 4 and grade 3 hepatotoxicity respectively. In both cases, a positive de-challenge was observed and concomitant drugs were not considered to be confounders. Hence, Remdesivir has a causal relationship with the occurrence of this adverse drug reaction.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. The New England journal of medicine, 2020;383(19):1813-1826.
Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. The American journal of Chinese medicine,2020;48(3):737-762.
MoHFW, Clinical management protocol: COVID-19, ministry of health and family welfare, directorate general of health services (EMR Division), 2020; 4: 1-20.
David S, Hamilton JP. Drug-induced Liver Injury. US gastroenterology & hepatology review, 2010;6:73-80.
Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS central Science, 2020;6(5):672-83.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe covid-19. The New England journal of medicine, 2020; 382(24): 2327–2336.
Li Y, Cai H, Rajabalee N, Au X, Friedenberg F, Wallach S. S1027 Hepatotoxicity of Remdesivir for COVID-19: Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, 2020; 115: S523
aLiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
bLiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Chembiochem : a European journal of chemical biology, 2020;21(5):730-738.
Mrinal Kaushik, Pharmacology basics and clinical aspects, Universities Press, 2011; 752. ISBN 10: 8173716943 ISBN 13: 9788173716942
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics, 1981;30(2):239-245.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 2020; 395(10236): 1569-1578.
Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 2016;531(7594):381-385.
WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. The New England journal of medicine, 2021;384(6):497-511.
Copyright (c) 2021 Harsh H. Patel, Harsha D. Makwana, Karan B. Shah, Supriya D. Malhotra
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.